vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and UNITED COMMUNITY BANKS INC (UCB). Click either name above to swap in a different company.
UNITED COMMUNITY BANKS INC is the larger business by last-quarter revenue ($276.5M vs $191.2M, roughly 1.4× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 11.6%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 6.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
United Community is an American bank. United is one of the largest full-service financial institutions in the Southeast, with $27.7 billion in assets and 200 offices in Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. In addition to its presence in the Southeast, United Community is the largest bank headquartered in South Carolina by total asset size.
AXSM vs UCB — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $276.5M |
| Net Profit | — | $84.3M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 30.5% |
| Revenue YoY | 57.4% | 11.6% |
| Net Profit YoY | — | 18.0% |
| EPS (diluted) | — | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $276.5M | ||
| Q4 25 | $196.0M | $278.4M | ||
| Q3 25 | $171.0M | $276.8M | ||
| Q2 25 | $150.0M | $260.2M | ||
| Q1 25 | $121.5M | $247.7M | ||
| Q4 24 | $118.8M | $250.9M | ||
| Q3 24 | $104.8M | $217.3M | ||
| Q2 24 | $87.2M | $245.3M |
| Q1 26 | — | $84.3M | ||
| Q4 25 | $-28.6M | $86.5M | ||
| Q3 25 | $-47.2M | $91.5M | ||
| Q2 25 | $-48.0M | $78.7M | ||
| Q1 25 | $-59.4M | $71.4M | ||
| Q4 24 | $-74.9M | $75.8M | ||
| Q3 24 | $-64.6M | $47.3M | ||
| Q2 24 | $-79.3M | $66.6M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 40.5% | ||
| Q3 25 | -27.0% | 42.6% | ||
| Q2 25 | -24.5% | 38.6% | ||
| Q1 25 | -46.9% | 36.8% | ||
| Q4 24 | -61.1% | 38.4% | ||
| Q3 24 | -59.8% | 27.5% | ||
| Q2 24 | -89.5% | 35.1% |
| Q1 26 | — | 30.5% | ||
| Q4 25 | -14.6% | 31.1% | ||
| Q3 25 | -27.6% | 33.0% | ||
| Q2 25 | -32.0% | 30.3% | ||
| Q1 25 | -48.9% | 28.8% | ||
| Q4 24 | -63.1% | 30.2% | ||
| Q3 24 | -61.7% | 21.8% | ||
| Q2 24 | -91.0% | 27.2% |
| Q1 26 | — | $0.69 | ||
| Q4 25 | $-0.55 | $0.71 | ||
| Q3 25 | $-0.94 | $0.70 | ||
| Q2 25 | $-0.97 | $0.63 | ||
| Q1 25 | $-1.22 | $0.58 | ||
| Q4 24 | $-1.54 | $0.61 | ||
| Q3 24 | $-1.34 | $0.38 | ||
| Q2 24 | $-1.67 | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $493.1M |
| Total DebtLower is stronger | $70.0M | $205.5M |
| Stockholders' EquityBook value | — | $3.7B |
| Total Assets | $713.6M | $28.2M |
| Debt / EquityLower = less leverage | — | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $493.1M | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | $205.5M | ||
| Q4 25 | — | $120.4M | ||
| Q3 25 | — | $155.3M | ||
| Q2 25 | — | $155.1M | ||
| Q1 25 | — | $254.3M | ||
| Q4 24 | — | $254.2M | ||
| Q3 24 | — | $316.4M | ||
| Q2 24 | — | $324.9M |
| Q1 26 | — | $3.7B | ||
| Q4 25 | $88.3M | $3.6B | ||
| Q3 25 | $73.7M | $3.6B | ||
| Q2 25 | $73.1M | $3.6B | ||
| Q1 25 | $53.2M | $3.5B | ||
| Q4 24 | $57.0M | $3.4B | ||
| Q3 24 | $92.9M | $3.4B | ||
| Q2 24 | $102.9M | $3.3B |
| Q1 26 | $713.6M | $28.2M | ||
| Q4 25 | $689.8M | $28.0B | ||
| Q3 25 | $669.3M | $28.1B | ||
| Q2 25 | $639.8M | $28.1B | ||
| Q1 25 | $596.7M | $27.9B | ||
| Q4 24 | $568.5M | $27.7B | ||
| Q3 24 | $561.5M | $27.4B | ||
| Q2 24 | $548.2M | $27.1B |
| Q1 26 | — | 0.06× | ||
| Q4 25 | — | 0.03× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
UCB
| Deposits | $98.0M | 35% |
| Investment securities, including tax exempt of $1,646 and $1,678, respectively | $45.3M | 16% |
| Money market | $40.7M | 15% |
| Time | $28.7M | 10% |
| NOW and interest-bearing demand | $28.1M | 10% |
| Service charges and fees | $9.5M | 3% |
| Other | $8.0M | 3% |
| Mortgage loan gains and other related fees | $8.0M | 3% |
| Wealth management fees | $4.6M | 2% |
| Lending and loan servicing fees | $4.0M | 1% |
| Deposits in banks and short-term investments | $1.2M | 0% |
| Securities gains, net | $133.0K | 0% |
